Cell Therapy News Volume 22.34 | Sep 27 2021

    By
    Justin.choi
    -
    0
    38







    2021-09-27 | CTN 22.34


    Cell Therapy News by STEMCELL Technologies
    Vol. 22.34 – 27 September, 2021
    TOP STORY

    T Lymphocyte Membrane-Decorated Epigenetic Nanoinducer of Interferons for Cancer Immunotherapy

    Scientists created a T lymphocyte membrane-decorated epigenetic nanoinducer that was engineered with programmed cell death protein 1 (PD1), which they called OPEN, for the delivery of the IFN inducer ORY-1001.
    [Nature Nanotechnology]

    Abstract

    Watch the webinar where Dr. Suzan Imren discusses factors affecting the balance between HSC self-renewal and leukemic transformation
    PUBLICATIONSRanked by the impact factor of the journal

    Short-Term Preclinical Application of Functional Human Induced Pluripotent Stem Cell-Derived Airway Epithelial Patches

    Airway epithelial patches were engineered by differentiating human iPSC-derived airway progenitors into physiological proportions of ciliated and goblet cells on a silk fibroin–collagen vitrigel membrane composite biomaterial for transplantation in porcine tracheal defects ex vivo and in vivo.
    [Advanced Healthcare Materials]

    Abstract

    Mitochondrial Augmentation of CD34+ Cells from Healthy Donors and Patients with Mitochondrial DNA Disorders Confers Functional Benefit

    Investigators described a method of ex vivo augmentation of hematopoietic stem and progenitor cells (HSPCs) with normal exogenous mitochondria, termed mitochondrial augmentation therapy.
    [NPJ Regenerative Medicine]

    Full Article

    Impact of Mother Donor, Peripheral Blood Stem Cells and Measurable Residual Disease on Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Children with Acute Leukemia

    Researchers analyzed 144 acute leukemia haploidentical hematopoietic-cell transplantation using post-transplant cyclophosphamide pediatric recipients; median age was ten years.
    [Bone Marrow Transplantation]

    Abstract

    Altered Effect of Killer Immunoglobulin-Like Receptor–Ligand Mismatch by Graft versus Host Disease Prophylaxis in Cord Blood Transplantation

    The difference in the effect of killer immunoglobulin-like receptor–ligand mismatch (KIR)–ligand mismatch was retrospectively assessed between patients who received cord blood transplantation for acute leukemia, myelodysplastic syndrome, or chronic myeloid leukemia, as well as graft-versus-host-disease prophylaxis comprising tacrolimus plus methotrexate or mycophenolate mofetil.
    [Bone Marrow Transplantation]

    Abstract

    Combination of Antioxidant Enzyme Overexpression and N‐Acetylcysteine Treatment Enhances the Survival of Bone Marrow Mesenchymal Stromal Cells in Ischemic Limb in Mice with Type 2 Diabetes

    Critical limb ischemia in type 2 diabetes mouse model was used to explore the impact of diabetic limb ischemia on the survival of bone marrow mesenchymal stromal cells.
    [Journal of the American Heart Association]

    Abstract

    Retinoic Acid and Taurine Enhance Differentiation of the Human Bone Marrow Stem Cells into Cone Photoreceptor Cells and Retinal Ganglion Cells

    The authors investigated the effect of retinoic acid and taurine in differentiation of the human bone marrow stem cell into cone photoreceptors cells and retinal ganglion cells.
    [Journal of Cellular Biochemistry]

    Abstract

    Impact of Allogeneic Stem Cell Transplantation Comorbidity Indexes after Haplotransplant Using Post-Transplant Cyclophosphamide

    The impact of three different scoring system used to to assess to assess pre-transplant comorbidity in allogeneic hematopoietic stem cell transplantation (ALL-HSCT) survivals and NRM was examined in a cohort of 223 patients treated with haploidentical Allo-HSCT in four different centers.
    [Cancer Medicine]

    Full Article

    Amniotic Fluid Stem Cell Administration Can Prevent Epithelial Injury from Necrotizing Enterocolitis

    The authors examined the effects of amniotic fluid and mesenchymal stem cells on the prevention of intestinal injury during experimental necrotizing enterocolitis.
    [Pediatric Research]

    Abstract

    Oxaliplatin Facilitates Tumor-Infiltration of T Cells and Natural-Killer Cells for Enhanced Tumor Immunotherapy in Lung Cancer Mode

    Subcutaneous A549 lung cancer and murine Lewis lung carcinoma (LLC) models were constructed, which were further intravenously injected with platinum-based drugs or concomitant administrated with anti-PD-1 antibody and or anti-natural-killer group 2, member D antibody.
    [Anti-Cancer Drugs]

    Abstract
    Science is demanding. That's why scientists work smart.
    REVIEWS

    Genome Edited B Cells: A New Frontier in Immune Cell Therapies

    Investigators discuss the potential of engineered B cells as a cell therapy, the challenges involved in editing the Ig locus and the advances that are making this possible, and envision future directions for this emerging field of immune cell engineering.
    [Molecular Therapy]

    AbstractGraphical Abstract

    Hypoxia Conditioned Mesenchymal Stem Cells in Tissue Regeneration Application

    The authors summarize current knowledge of hypoxia-induced changes in mesenchymal stem cells (MSCs) and discuss the application of hypoxia preconditioned MSCs as well as hypoxic secretome in different kinds of disease models.
    [Tissue Engineering Part B-Reviews]

    Abstract
    INDUSTRY AND POLICY NEWS

    bluebird bio Submits Biologics License Application (BLA) to FDA for Betibeglogene Autotemcel (Beti-Cel) Gene Therapy for Patients with β-Thalassemia Who Require Regular Red Blood Cell Transfusions

    bluebird bio, Inc. announced it has completed the rolling submission of its BLA to the US FDA for beti-cel gene therapy in adult, adolescent and pediatric patients with β-thalassemia who require regular red blood cell transfusions, across all genotypes.
    [bluebird bio, Inc.]

    Press Release

    Revolutionary New Cancer CAR-T Cell Therapy Treatment World-First in New Zealand

    A revolutionary new cancer treatment has arrived in New Zealand in the form of a cocoon. The machine is used for what is called CAR-T cell therapy, which reprogrammes a patient’s cells to fight their cancer.
    [NewsHub]

    Press Release

    FEATURED EVENT

    Genome Editing: All Things Considered (CSHL)

    November 28 – December 2, 2021
    Suzhou, China

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Scientist – Drug Discovery Sciences

    Boehringer Ingelheim – Biberach, Germany

    Research Assistant – Regenerative Medicine for the Biliary System

    University of Cambridge – Cambridge, England, United Kingdom

    Postdoctoral Position – Stem Cells and Disease Modeling

    King Abdullah University of Science and Technology – Thuwal, Saudi Arabia

    Head of Laboratory – Cellular Therapies

    NHS Blood and Transplant – Oxford, England, United Kingdom

    Senior Scientist – Gene Editing

    Cellectis – Paris, France

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cell Therapy News Twitter